Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1533-1542

  Shangary, Sanjeev ^a,b   Ding, Ke ^a,b   Qiu, Su ^a,b   Nikolovska Coleska, Zaneta ^a,b   Bauer, Joshua A ^a,b   Liu, Meilan ^a,b   Wang, Guoping ^a,b   Lu, Yipin ^a,b   McEachern, Donna ^a,b   Bernard, Denzil ^a,b   Bradford, Carol R ^a,b   Carey, Thomas E ^a,b   Wang, Shaomeng ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MI 43; NUTLIN 3; OXINDOLE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SPIRO COMPOUND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOCHROME C; DIABLO PROTEIN, HUMAN; INDOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; MI 43 COMPOUND; MITOCHONDRIAL PROTEIN; PHOSPHOSERINE; SIGNAL PEPTIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL STRAIN HCT116; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; COLON TUMOR; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PATHOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOCHROMES C; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; PHOSPHOSERINE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; SPIRO COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 49849104827     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0140     Document Type: Article

References (27)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
3. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007;85:1175-86.
4. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001;29:684-8.
5. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
6. Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004;52:103-16.
7. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
8. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
9. Juven-Gershon T, Oren M. Mdm2: the ups and downs. Mol Med 1999;5:71-83.
10. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107-14.
11. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994;9:2523-9.
12. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274:948-53.
13. Chene P. Inhibiting the p53-2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003;3:102-9.
14. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
15. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13:23-31.
16. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007;128:837-40.
17. Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 2005;127:10130-1.
18. Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-53 interaction. J Med Chem 2006;49:3432-5.
19. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444:61-6.
20. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther 2005;4:23-31.
21. Verhaegen M, Bauer JA, Martin de la Vega C, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006;66:11348-59.
22. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNAin terference. Cancer Cell 2002;2:243-7.
23. Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004;279:53015-22.
24. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
25. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-93.
26. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996;10:2438-51.
27. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 2008;105:3933-8.